Pulmonary Hypertension: Beyond Vasodilators
Deadline Aug 6 2021 11:59 PM (EDT)
Description

Event Date: October 12, 2021
Deadline to Submit Abstracts: August 6, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Pulmonary hypertension (PH) is a highly morbid condition without cure. Some forms of PH, such as Pulmonary Arterial Hypertension (PAH) have a mean survival of 5-years after diagnosis with mortality most commonly due to right heart failure. Current therapies include several classes of vasodilators, including prostacyclins, calcium channel blockers, PDE5 inhibitors, endothelin receptor antagonists (ETRA), and soluble guanylate cyclase stimulators, all of which are limited by systemic hypotension. Several agents including ETRA and prostacyclin have additional dose-limiting systemic side effects or toxicities. Moreover, many patients are unresponsive to these agents at diagnosis or during the course of therapy, due to advanced disease, progression, or drug tachyphylaxis. Given these limitations, there is a strong need for new therapies beyond vasodilators acting by novel anti-proliferative, anti­fibrotic, or anti-inflammatory mechanisms to modify the natural history of disease. This virtual symposium will convene basic researchers, clinicians, and drug developers to discuss latest advances in the development of novel therapeutics that can overcome the limitations of current therapy for PH.

To register for this event, please visit the main website at: nyas.org/PH2021

Apply

Pulmonary Hypertension: Beyond Vasodilators


Event Date: October 12, 2021
Deadline to Submit Abstracts: August 6, 2021

This application is for a virtual Poster Presentation. Poster submissions may also be considered for Short Talks. See here for submission guidelines.

Pulmonary hypertension (PH) is a highly morbid condition without cure. Some forms of PH, such as Pulmonary Arterial Hypertension (PAH) have a mean survival of 5-years after diagnosis with mortality most commonly due to right heart failure. Current therapies include several classes of vasodilators, including prostacyclins, calcium channel blockers, PDE5 inhibitors, endothelin receptor antagonists (ETRA), and soluble guanylate cyclase stimulators, all of which are limited by systemic hypotension. Several agents including ETRA and prostacyclin have additional dose-limiting systemic side effects or toxicities. Moreover, many patients are unresponsive to these agents at diagnosis or during the course of therapy, due to advanced disease, progression, or drug tachyphylaxis. Given these limitations, there is a strong need for new therapies beyond vasodilators acting by novel anti-proliferative, anti­fibrotic, or anti-inflammatory mechanisms to modify the natural history of disease. This virtual symposium will convene basic researchers, clinicians, and drug developers to discuss latest advances in the development of novel therapeutics that can overcome the limitations of current therapy for PH.

To register for this event, please visit the main website at: nyas.org/PH2021

Apply
Deadline
Aug 6 2021 11:59 PM (EDT)